Please join us to learn about the burden of disease and existing unmet needs in the management of systemic lupus erythematosus (SLE), as well as the mechanism of action and clinical profile of an FDA-approved novel treatment option. A real-world patient case example will also be discussed. Developed and offered by AstraZeneca.
Non-CME
